Brazil dengue vaccine deaths raise concerns for India's upcoming DengiAll vaccine
Recent deaths of two people in Brazil during its dengue vaccination campaign, linked to the Butantan-DV vaccine, have raised concerns for India's upcoming DengiAll vaccine, which is structurally similar. Both vaccines are tetravalent, live-attenuated versions of dengue viruses (DENVs) developed using NIH technology. The Brazilian cases involved 42 recipients with severe side-effects, including two deaths, prompting vaccine suspension. Medical researchers are urged to investigate if antibody-dependent enhancement (ADE) is responsible for these severe events. India is advised to proactively analyze type-specific antibodies in vaccinated volunteers and implement a robust pharmacovigilance program for DengiAll to ensure safety and monitor long-term adverse events, learning from past issues with Sanofi Pasteur's Dengvaxia.
Key Points
- Two deaths in Brazil linked to the Butantan-DV dengue vaccine have raised safety concerns for India's similar DengiAll vaccine.
- Both Butantan-DV and DengiAll are tetravalent, live-attenuated vaccines based on NIH technology.
- Severe adverse events, including deaths, occurred in Brazil among 42 vaccine recipients, leading to vaccine suspension.
- Medical researchers need to investigate if antibody-dependent enhancement (ADE) is causing these severe outcomes.
- India should proactively implement robust pharmacovigilance and analyze type-specific antibodies for DengiAll before its rollout.
Exam Facts
- Brazilian dengue vaccine: Butantan-DV.
- India's upcoming dengue vaccine: DengiAll.
- Technology developed at: U.S. National Institutes of Health (NIH).
- Previous dengue vaccine with issues: Sanofi Pasteur's Dengvaxia, given in the Philippines.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.